Chromogranin A (CgA) serum level as a marker of progression in hepatocellular carcinoma (HCC) of elderly patients

Malaguarnera, Michele; Vacante, Marco; Fichera, Rosangela; Cappellani, Alessandro; Cristaldi, Erika; Motta, Massimo

doi:10.1016/j.archger.2009.08.004

« Previous Next »Archives of Gerontology and Geriatrics
Volume 51, Issue 1 , Pages 81-85, July 2010

Chromogranin A (CgA) serum level as a marker of progression in hepatocellular carcinoma (HCC) of elderly patients

Michele Malaguarnera
- Department of Senescence, Urological and Neurological Sciences, Cannizzaro Hospital, University of Catania, Via Messina 829, I-95124 Catania, Italy
Marco Vacante
- Department of Senescence, Urological and Neurological Sciences, Cannizzaro Hospital, University of Catania, Via Messina 829, I-95124 Catania, Italy
Rosangela Fichera
- Department of Senescence, Urological and Neurological Sciences, Cannizzaro Hospital, University of Catania, Via Messina 829, I-95124 Catania, Italy
Alessandro Cappellani
- Department of Surgery of “Policlinico Gaspare Rodolico”, University of Catania, Via Santa Sofia 86, I-95123 Catania, Italy
Erika Cristaldi
- Department of Senescence, Urological and Neurological Sciences, Cannizzaro Hospital, University of Catania, Via Messina 829, I-95124 Catania, Italy
Massimo Motta
- Department of Senescence, Urological and Neurological Sciences, Cannizzaro Hospital, University of Catania, Via Messina 829, I-95124 Catania, Italy
- Corresponding author. Tel.: +39 095 726 2050; fax: +39 095 498 811.

Received 29 April 2009; received in revised form 10 August 2009; accepted 13 August 2009. published online 22 September 2009.

Abstract

The observation of neuroendocrine (NE) activity during clinical course of hepatocellular carcinoma (HCC), suggested the use of NE serum markers to detect it. Thus we have evaluated the usefulness of serum measurements of CgA in monitoring disease activity of HCC. We investigated the role of serum concentrations of CgA, α-fetoprotein (AFP) and des-γ-carboxyl-prothrombin (DCP) in 55 patients with HCC, 27 patients with cirrhosis, 22 patients with chronic hepatitis and a control group of 20 volunteers and the relationship between the pre-treatment serum CgA and clinical stages of the disease. CgA was significantly higher in the patients affected by HCC as compared with those affected by either hepatitis or cirrhosis (p<0.001). We also observed significant differences, comparing CgA serum levels in the tumor classes T1–T4: T1 vs. T2 (p<0.001), T1 vs. T3 (p<0.001), T1 vs. T4 (p<0.001), T2 vs. T3 (p<0.001), T2 vs. T4 (p<0.001) and T3 vs. T4 (p<0.001). CgA levels were significantly higher in poorly differentiated HCC vs. well differentiated (p<0.05) and medium differentiated ones (p<0.001). Also the comparison between Child-Pugh degree A and C showed a significant difference in CgA levels (p<0.001). Thereby, patients with higher CgA level had poor survival and showed poor prognosis, compared to those with lower CgA level, i.e., the CgA is useful in monitoring progression of disease and may assist as a prognostic indicator.